GlassScriptPhysician profile
Vikram Grewal
NPI 1528485620
$13,499.61
in general payments reported to CMS, 2019-2025
45 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2020: $418 · 2021: $3,416 · 2022: $2,789 · 2023: $2,950 · 2024: $2,285 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,767 · Education: $98.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,766.60 |
| Education | $98.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,935.04 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,866.21 | 2020-2025 | Farxiga, Airsupra, Lokelma |
| Abbott Laboratories | $1,171.65 | 2020-2025 | Mitraclip, Aveir, Cardiomems |
| Amgen INC. | $996.38 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $978.82 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $716.48 | 2021-2025 | |
| Pfizer INC. | $684.04 | 2019-2025 | |
| Novo Nordisk INC | $518.99 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $439.90 | 2021-2024 | Azure Xt Dr Mri Surescan, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.66 | 2021-2025 | Jardiance |
| Biotronik INC. | $377.63 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $333.80 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $303.01 | 2021-2023 | Verquvo, Belsomra |
| Boston Scientific Corporation | $301.14 | 2022-2023 | Watchman Access System, Varithena Administration Pack |
| Harmony Biosciences LLC | $258.13 | 2021-2025 | Wakix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.